Revenue: As of FY2025 Q1, the actual value is USD 517 K.EPS: As of FY2025 Q1, the actual value is USD 0.28.<h3>Segment Revenue</h3><ul><li>Product Revenue, Net: $147,000 for the three months ended March 31, 2025.</li><li>Contract Revenue: $370,000 for the three months ended March 31, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $39,139,000 for the three months ended March 31, 2025, compared to a net loss of $31,896,000 for the same period in 2024.</li><li>Loss from Operations: - $23,184,000 for the three months ended March 31, 2025, compared to - $26,578,000 for the same period in 2024.</li><li>Research and Development Expenses: $15,418,000 for the three months ended March 31, 2025, a decrease from $21,264,000 for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $8,136,000 for the three months ended March 31, 2025, an increase from $5,314,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $28,601,000 for the three months ended March 31, 2025, compared to - $27,347,000 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $228,000 for the three months ended March 31, 2025, compared to - $391,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $46,739,000 for the three months ended March 31, 2025, compared to $62,795,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of Contingent Earnout Liability: $49,731,000 gain for the three months ended March 31, 2025, compared to a - $4,593,000 loss for the same period in 2024.</li><li>Change in Fair Value of Derivatives: $14,930,000 gain for the three months ended March 31, 2025, compared to a $60,000 gain for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and scale its manufacturing facility to meet market demand.</li><li>Non-Core Business: The company is exploring applications of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.</li><li>Priority: The company estimates savings from workforce and other operating cost reductions, and reduced capital expenditures, totaling approximately $13.8 million in 2025 and up to approximately $38.0 million in 2026.</li></ul>

Humacyte - CW27 | 10-Q: FY2025 Q1 Revenue: USD 517 K